The global esoteric testing market size accounted for USD 33.50 billion in 2024, grew to USD 37.08 billion in 2025 and is predicted to surpass around USD 92.57 billion by 2034, representing a healthy CAGR of 10.70% between 2024 and 2034. The North America esoteric testing market size is calculated at USD 14.41 billion in 2024 and is expected to grow at a fastest CAGR of 10.82% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Esoteric Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Esoteric Testing Market, by Type, 2024-2034
8.1.1 Infectious Diseases Testing
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Endocrinology Testing
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Oncology Testing
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Genetics Testing
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Toxicology Testing
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Immunology Testing
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Neurology Testing
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Other Testing
8.1.8.1. Market Revenue and Forecast (2021-2034)
9.1. Esoteric Testing Market, by Technology, 2024-2034
9.1.1. Chemiluminescence Immunoassay
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Enzyme-Linked Immunosorbent Assay
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Mass Spectrometry
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Real-Time PCR
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. DNA Sequencing
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Flow Cytometry
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Other Technologies
9.1.7.1. Market Revenue and Forecast (2021-2034)
10.1. Esoteric Testing Market, by End User, 2024-2034
10.1.1. Independent & Reference Laboratories
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Hospital-Based Laboratories
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.1. ACM Global Laboratories (US)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. ARUP Laboratories (US).
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Baylor Esoteric and Molecular Laboratory (US)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioAgilytix Labs (US)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BP Diagnostic Centre SDN BHD (Malaysia)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. BUHLMANN Diagnostics Corp (BDC, US)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cerba Xpert (Belgium)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Eurofins Scientific (Luxembourg)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Flow Health (US)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Foundation Medicine (US)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample